Dr. Shi is the General Manager of Shenzhen EXUMA Biotech, overseeing supply chain, manufacturing, quality control, and site operations at the Company’s lentivector manufacturing facility.  Prior to EXUMA, he served as Vice President, CMC and Site Head of EdiGene where he led the development of the first gene editing HSC therapy in China.  Prior to that, he held R&D and QA roles at Xiangxue Pharmaceutical in which he was responsible for the development of analytical methods for TCR-T product manufacturing; his work led to the first IND approval for a TCR-T product candidate in China.

Dr. Shi received his Ph.D. in physiology from China Agriculture University and holds the Senior Specialized Technique Qualification from the Beijing Municipal Medical Products Administration.